Document Detail

European experience with ifosfamide in non-small cell lung cancer.
MedLine Citation:
PMID:  2539645     Owner:  NLM     Status:  MEDLINE    
Ifosfamide is one of the most effective cytostatics for the treatment of lung carcinomas. For non-small cell lung cancer (NSCLC), in particular, the administration of 1.5 to 2.0 g/m2 on five successive days at intervals of 3 to 4 weeks has been found optimal. Used in combination with one or two cytotoxic agents, ifosfamide has achieved higher remission rates and longer periods of remission than single-drug chemotherapy. This result also is reflected in the longer median survival of successfully treated patients. The results of chemotherapy with ifosfamide combinations are comparable with those using cisplatin combinations. Because of considerably better tolerance, ifosfamide combinations are preferred, particularly when cisplatin is used in a moderate to high dose. At our institution, 192 untreated patients with histologically verified NSCLC were treated in three phase-II studies with different chemotherapy regimens: ifosfamide, 2 g/m2 days 1 to 5, and cisplatin, 75 mg/m2 on day 1 (study I); ifosfamide, 2 g/m2 days 1 to 5, and etoposide, 120 mg/m2 days 1 to 3 (study II); and ifosfamide, 2 g/m2 days 1 to 5, and vindesine, 3 mg/m2 on days 1 and 8 (study III). All chemotherapy combinations were repeated every 4 weeks. At least two courses of therapy were necessary to evaluate remission rate. We observed complete remissions in five patients and partial remissions in 54, for a total remission rate. of 31%. The median duration of remission was 7 months, and the time to progression was 5 months. Median survival time of all 192 patients was 8.5 months. Performance status significantly influenced the remission rate and survival time. Sex and age as well as the tumor extent and histologic type had no influence on remission. No significant differences among the three therapy regimens were seen in remission rate and survival time. The ifosfamide/etoposide combination was the preferred regimen in terms of toxicity.
P Drings
Related Documents :
9473755 - A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric...
2646005 - High-dose, double alkylating agent chemotherapy with dtic, melphalan, or ifosfamide and...
10928155 - Low dose adriamycin and ifosfamide in the treatment of advanced adult soft tissue sarco...
2503255 - Phase ii study of ifosfamide as a single drug for relapsed paediatric patients.
19349865 - Treatment of radiation retinopathy following plaque brachytherapy for choroidal melanoma.
18653395 - Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (mp...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Seminars in oncology     Volume:  16     ISSN:  0093-7754     ISO Abbreviation:  Semin. Oncol.     Publication Date:  1989 Feb 
Date Detail:
Created Date:  1989-05-15     Completed Date:  1989-05-15     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  0420432     Medline TA:  Semin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  22-30     Citation Subset:  IM    
Department of Medical Oncology, Thoraxklinik Heildelberg-Rohrbach, FRG.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Cisplatin / administration & dosage,  adverse effects
Drug Evaluation
Etoposide / administration & dosage,  adverse effects
Ifosfamide / administration & dosage*,  adverse effects
Lung Neoplasms / drug therapy*
Middle Aged
Remission Induction
Vindesine / administration & dosage,  adverse effects
Reg. No./Substance:
15663-27-1/Cisplatin; 33419-42-0/Etoposide; 3778-73-2/Ifosfamide; 53643-48-4/Vindesine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ifosfamide in small cell lung cancer.
Next Document:  Ifosfamide in the treatment of non-small cell lung cancer.